Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 9Genitourinary 7Gastrointestinal 6Lymphoid 5CNS 5Myeloid 4Gynecologic 3Plasma cell 2Head & Neck 2Endocrine 2Tumor-Agnostic 1Thoracic 1NET 1Dermatologic 1Breast 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 8Specimen Handling 5Magnetic Resonance Spectroscopy 5pembrolizumab 3Everolimus 3cabozantinib 2X-Rays 2repotrectinib 1peposertib 1pazopanib 1olaparib 1lenvatinib 1fludarabine 1entrectinib 1belinostat 1aldesleukin 1Watchful Waiting 1Tomography, X-Ray Computed 1Tomography, Emission-Computed, Single-Photon 1Sunitinib 1Single Photon Emission Computed Tomography Computed Tomography 1Salts 1Positron Emission Tomography Computed Tomography 1Photons 1Phantoms, Imaging 1PT-100 dipeptide 1Octreotide 1Nivolumab 1Lutetium-177 1Lutetium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phantoms, Imaging × NET × 30 days × Clear all
NCT01841736 2026-05-27

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
171 enrolled 15 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡